prikaz prve stranice dokumenta More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features
  Download
PDF 1.31 MB
Scientific paper - Original scientific paper
More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features
Therapeutics and Clinical Risk Management, 17 (2021); 1037-1044. https://doi.org/10.2147/TCRM.S323749
Lucijanić, Marko; Huzjan Korunić, Renata; Sedinic, Martina; Kušec, Rajko; Pejša, Vlatko

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Lucijanić, M., Huzjan Korunić, R., Sedinic, M., Kušec, R. & Pejša, V. (2021). More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features. Therapeutics and Clinical Risk Management, 17., 1037-1044. doi: 10.2147/TCRM.S323749

Lucijanić, Marko, et al. "More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features." Therapeutics and Clinical Risk Management, vol. 17, 2021, pp. 1037-1044. https://doi.org/10.2147/TCRM.S323749

Lucijanić, Marko, Renata Huzjan Korunić, Martina Sedinic, Rajko Kušec and Vlatko Pejša. "More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features." Therapeutics and Clinical Risk Management 17 (2021): 1037-1044. https://doi.org/10.2147/TCRM.S323749

Lucijanić, M., et al. (2021) 'More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features', Therapeutics and Clinical Risk Management, 17, pp. 1037-1044. doi: 10.2147/TCRM.S323749

Lucijanić M, Huzjan Korunić R, Sedinic M, Kušec R, Pejša V. More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features. Therapeutics and Clinical Risk Management [Internet]. 2021 September 24 [cited 2024 December 27];17:1037-1044. doi: 10.2147/TCRM.S323749

M. Lucijanić, R. Huzjan Korunić, M. Sedinic, R. Kušec and V. Pejša, "More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features", Therapeutics and Clinical Risk Management, vol. 17, pp. 1037-1044, September 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:931158. [Accessed: 27 December 2024]

Metadata
Title (english)More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features
AuthorMarko Lucijanić
AuthorRenata Huzjan Korunić
AuthorMartina Sedinic
AuthorRajko Kušec
AuthorVlatko Pejša
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Introduction: Cancer-induced cachexia is associated with poor prognosis in patients with non-Hodgkin lymphoma, but it is unknown how and to what extent curable lymphoma treatments affect the musculoskeletal system. ----- Patients and methods: We retrospectively analyzed 104 newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with unfavorable disease features treated with the R-DA-EPOCH regimen. Psoas muscle area (PMA) measured at L3 vertebra level was compared between staging (pre-therapy) and revision (end of treatment) computerized tomography (CT) scans. ----- Results: Small but significant decline in PMA was observed during the immunochemotherapy period (average loss 5%; P=0.016) with 57.7% of patients experiencing muscle loss. Higher body surface area (OR=17.98 for each m2; P=0.034), number of cycles with dose reduction (OR=2.86 for each cycle; P=0.039) and worse response to therapy (OR=3.09 for each response category; P=0.052) were recognized as independent contributors to the PMA loss in multivariate analysis. One quarter of patients had more pronounced PMA loss (≥21%), which was associated with significantly worse overall and progression-free survival. Both ≥21% PMA loss and non-achieving response to therapy remained independently associated with inferior OS (PMA loss HR=2.98; P=0.016 and achieving response HR=0.04; P<0.001) and PFS (PMA loss HR=3.16; P=0.005 and achieving response HR=0.08; P=0.001) in multivariate analyses. ----- Discussion: Muscle loss occurs in approximately half of newly diagnosed DLBCL patients with unfavorable disease features during R-DA-EPOCH immunochemotherapy. If pronounced, this is associated with worse clinical outcomes irrespectively of achieved response to therapy. Muscle loss seems to be mostly affected by the efficacy and tolerability of the regimen.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleTherapeutics and Clinical Risk Management
Numberingvol. 17, pp. 1037-1044
p-ISSN1176-6336
e-ISSN1178-203X
DOIhttps://doi.org/10.2147/TCRM.S323749
URN:NBNurn:nbn:hr:105:931158
Publication2021-09-24
Document URLhttps://www.dovepress.com/more-pronounced-muscle-loss-during-immunochemotherapy-is-associated-wi-peer-reviewed-fulltext-article-TCRM
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 3.0 Unported (CC BY-NC 3.0) icon
Created on2022-04-07 11:21:18